Apparently all I need to do is put out a cautious note and the market takes off. I am going to goose the market even more as I am still not convinced we are out of the woods. I do not see us at the end of the interest rate hikes and the Fed wants […]
October 3rd Biotech Update
I am really torn on the market right now. There is not a lot going on in biotech to make it really capable of swimming against the current (if the broader market weakens) and so I think macro really matters. I want to focus on two macro issues that I think are weighing on the […]
September 29th Biotech Update
As much as we had a good day early this week, the market looks really tenuous. I have seen some statistics about position that look quite bullish (i.e. investors are extremely under-invested) but I have also seen some statistics that show the interest rates have move very fast and the market needs to catch up […]
September 27th Biotech Update
The broader market continues to have issues with rates and inflation, although the sector did a little better yesterday. I fully expect the sector to outperform today and would be quite disappointed if not for a longer period of time. We finally have something to be a little excited about and it came from a […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
